To our knowledge, IGFBP2 is the first gene that serves as a prognostic marker in IDH-mutant glioma patients; in particular, increased IGFBP2 expression in IDH-mutant glioma patients is prognostic of poor outcomes worse than those of IDH-wildtype glioma patients. This evidence concerns the gene IDH1 and glioma.